New Insights on Respiratory Syncytial Virus Prevention
Respiratory syncytial virus (RSV) is a well-known infant pathogen transmitted mainly by droplets. It is a leading cause of upper respiratory tract infections in children, usually with a mild course of illness. RSV has also been a threat to older people, especially those with underlying medical condi...
Main Authors: | Edyta Kopera, Hanna Czajka, Paweł Zapolnik, Artur Mazur |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/12/1797 |
Similar Items
-
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
by: Tyler Brady, et al.
Published: (2023-10-01) -
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
by: Gary M. Ginsberg, et al.
Published: (2018-12-01) -
Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana
by: Nuttapat Pisuttinusart, et al.
Published: (2024-12-01) -
Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus
by: Bo-Wen Sun, et al.
Published: (2024-01-01) -
The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
by: Emanuele Andreano, et al.
Published: (2021-06-01)